The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD) common stock between November 29, 2021 and December 14, 2021.
According to the Invivyd lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
If you suffered a loss in Invivyd you have until April 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.